TY - JOUR
T1 - Overview
T2 - Cardiovascular & renal; cyclic nucleotide phosphodiesterase inhibitors
AU - Demoliou-Mason, Catherine D.
PY - 1995/5/1
Y1 - 1995/5/1
N2 - Cyclic nucleotide phosphodiesterases (PDEs) hydrolyse cyclic nucleotides to their inactive form (5' nucleotides), and thereby play an important role in cellular signalling mechanisms. These enzymes can be classed into seven families (or isozymes/isoenzymes) on the basis of their amino acid sequence, substrate specificity and sensitivity to pharmacological agents. This article reviews each PDE family in turn and analyses the patent literature in each area. Specific attention has been placed on those patents which disclose compounds reported to be useful for the treatment of cardiovascular diseases including thrombosis and atherosclerosis.
AB - Cyclic nucleotide phosphodiesterases (PDEs) hydrolyse cyclic nucleotides to their inactive form (5' nucleotides), and thereby play an important role in cellular signalling mechanisms. These enzymes can be classed into seven families (or isozymes/isoenzymes) on the basis of their amino acid sequence, substrate specificity and sensitivity to pharmacological agents. This article reviews each PDE family in turn and analyses the patent literature in each area. Specific attention has been placed on those patents which disclose compounds reported to be useful for the treatment of cardiovascular diseases including thrombosis and atherosclerosis.
UR - http://www.scopus.com/inward/record.url?scp=0029001774&partnerID=8YFLogxK
U2 - 10.1517/13543776.5.5.417
DO - 10.1517/13543776.5.5.417
M3 - Article
AN - SCOPUS:0029001774
SN - 1354-3776
VL - 5
SP - 417
EP - 430
JO - Expert Opinion on Therapeutic Patents
JF - Expert Opinion on Therapeutic Patents
IS - 5
ER -
